Inhibrx Biosciences, Inc. share price logo

Inhibrx Biosciences, Inc. Share Price

NASDAQ: INBX

Small Cap

$26.52

-0.66

(-2.45%)

as on

Inhibrx Biosciences, Inc. Stock Performance

as on September 17, 2025 at 1:29 am IST

  • Day's Low

    Day's High

    $26.28
    $27.89
    downward going graph

    0.90%

    Downside

    5.17%

    Upside

    downward going graph

  • 52 Week's Low

    52 Week's High

    $10.81
    $30.23
    downward going graph

    59.26%

    Downside

    13.99%

    Upside

    downward going graph

Inhibrx Biosciences, Inc. share price movements today

Previous Close
$27.18
Open
$27.24
Volume
196.9K
Day's Low - High
$26.28 - $27.89
52 Week Low - High
$10.81 - $30.23

Inhibrx Biosciences, Inc. Historical Returns

1 Month Return
+ 13.89 %
3 Month Return
+ 81.99 %
1 Year Return
+ 54.3 %
3 Year Return
+ 83.75 %
5 Year Return
+ 44.17 %

Inhibrx Biosciences, Inc. Stock Fundamentals & Key Indicators

Check Inhibrx Biosciences, Inc. market cap, PE, PB, PEG ratios, dividend yield, and other key fundamental indicators.

Market Cap

$220.2M

EPS (TTM)

-10.74

Dividend Yield

0.00%

Quarterly Earnings Growth YOY

0.00%

PE Ratio (TTM)

0.13

Industry PE ratio

-4.207561643835616

P/B Ratio

0.1278

PEG Ratio

0

EBITDA

-229.9M

Revenue (TTM)

200.0K

Profit Margin

861485.50%

Return On Equity TTM

41.18%

Inhibrx Biosciences, Inc. Stock Valuation

Track how Inhibrx Biosciences, Inc. P/E has moved over time to understand its valuation trends.

Inhibrx Biosciences, Inc. in the last 5 years

  • Overview

  • Trends

Lowest (0.11x)

March 31, 2025

Industry (-4.21x)

September 17, 2025

Today (0.13x)

September 17, 2025

Highest (0.24x)

June 30, 2024

LowHigh

Today’s Price to Earnings Ratio: 0.13x

Inhibrx Biosciences, Inc. vs Peer Comparison

Compare market cap, revenue, PE, and other key metrics of Inhibrx Biosciences, Inc. with its industry peers.

Company
Analyst View
Market Cap
5 Years Return %PE RatioProfit Margin %
Inhibrx Biosciences, Inc. image
Inhibrx Biosciences, Inc.
HOLD$220.2M44.17%0.13861485.50%
Alnylam Pharmaceuticals, Inc. image
Alnylam Pharmaceuticals, Inc.
BUY$60.5B252.04%-505.15-12.96%
Beone Medicines Ltd image
Beone Medicines Ltd
NA$39.0BNANA-3.89%
Vertex Pharmaceuticals Incorporated image
Vertex Pharmaceuticals Incorporated
BUY$100.3B44.17%27.8531.86%
Regeneron Pharmaceuticals, Inc. image
Regeneron Pharmaceuticals, Inc.
BUY$59.6B1.78%14.131.37%

Stock Returns calculator for Inhibrx Biosciences, Inc. Stock including INR - Dollar returns

The Inhibrx Biosciences, Inc. stock calculator helps Indian investors calculate returns based on the historical performance of the stock. Just choose your investment amount and duration to get insights and invest more confidently. See stock returns as well as the effect of dollar appreciation over different durations.

*Dollar Return is the profit earned when the US dollar rises in value compared to the Indian rupee.

Investment Value

₹1,00,000

  • 1Y

  • 3Y

  • 5Y

Inhibrx Biosciences, Inc. investment value today

Current value as on today

₹1,58,874

Returns

₹58,874

(+58.87%)

Returns from Inhibrx Biosciences, Inc. Stock

₹54,007 (+54.01%)

Dollar Returns*

₹4,867 (+4.87%)

Analyst Recommendation on Inhibrx Biosciences, Inc. Stock

Based on 8 analysts

HOLD

0.00%

Buy

62.50%

Hold

37.50%

Sell

Based on 8 analysts, 62.5% of analysts recommend a 'HOLD' rating for Inhibrx Biosciences, Inc. . Average target price of $12

Inhibrx Biosciences, Inc. Share Price Target

Get share price movements and forecasts by analysts on Inhibrx Biosciences, Inc. .

What analysts predicted

-121%DOWNSIDE

Target Price

$12

Current Price

$26.52

Analyzed by

8 Analysts

Target

$12.00

Inhibrx Biosciences, Inc. target price $12, a slight downside of -121% compared to current price of $26.52. According to 8 analysts rating.

Inhibrx Biosciences, Inc. Stock's Interest Amongst Investors

Search interest for Inhibrx Biosciences, Inc. Stock has decreased by -50% in the last 30 days, reflecting a downward trend in search activity.

Time period: to

Change:-50% versus previous 30 day period

Inhibrx Biosciences, Inc. Quarterly Profit & Loss

All numbers in Millions USD

Mar 2023
Jun 2023
Sep 2023
Dec 2023
Mar 2024
Jun 2024
Sep 2024
Dec 2024
Mar 2025
Jun 2025
Total Revenue
0
0
0
1
-
0
-
0
-
1
Gross Profit
0
0
0
1
0
0
0
0
0
0
Operating Income
-43
-41
-45
-88
-73
-160
-46
-49
-42
-27
EBITDA
-41
-38
-43
-87
-70
1,863
-43
-47
-39
-27
Interest Expense
5
7
8
8
8
5
-
-
2
3
Depreciation
-
-
-
-
0
0
0
0
0
0
Income Before Tax
-48
-47
-51
-91
-78
1,858
-43
-47
-43
-28
Income Tax Expense
0
0
0
0
0
0
-
-
-
0
Net Income
-48
-47
-51
-93
-78
1,858
-43
-47
-43
-28
Net Profit Margin
-286417.65%
-156840.00%
-43520.17%
-5728.52%
0.00%
1858011.00%
0.00%
-47865.00%
0.00%
-2204.15%

Inhibrx Biosciences, Inc. Annual Profit & Loss

All numbers in Millions USD

Dec 2016
Dec 2017
Dec 2018
Dec 2019
Dec 2020
Dec 2021
Dec 2022
Dec 2023
Dec 2024
Total Revenue
6
7
7
9
12
7
2
1
0
Gross Profit
-10
-17
-25
-38
-60
4
-107
0
-2
Operating Income
-12
-19
-29
-43
-67
-76
-129
-219
-331
EBITDA
-11
-19
-28
-42
-66
-75
-125
-206
1,703
Interest Expense
-
2
1
5
10
5
16
31
13
Depreciation
-
-
-
-
-
-
1
1
2
Income Before Tax
-12
-21
-30
-50
-75
-81
-145
-239
1,687
Income Tax Expense
-4
0
0
0
0
0
0
0
0
Net Income
-8
-19
-31
-51
-75
-81
-145
-241
1,687
Net Profit Margin
-124.03%
-244.55%
-415.51%
-565.27%
-590.54%
-1147.62%
-6625.27%
-13408.94%
843786.00%

Inhibrx Biosciences, Inc. Quarterly Cash Flow

All numbers in Millions USD

Jun 2023
Sep 2023
Dec 2023
Mar 2024
Jun 2024
Sep 2024
Dec 2024
Mar 2025
Jun 2025
Net Income
-47
-51
-93
-78
1,828
-14
-47
-43
-28
Operating Cash Flow
-42
-54
-56
-63
-57
-30
-43
-35
-29
Investing Cash Flow
0
0
-3
-1
-1
0
0
0
-
Financing Cash Flow
0
199
0
38
32
2
-
99
-
Change in Cash
-41
144
-59
-25
-25
-30
-43
63
-29

Inhibrx Biosciences, Inc. Annual Cash Flow

All numbers in Millions USD

Dec 2017
Dec 2018
Dec 2019
Dec 2020
Dec 2021
Dec 2022
Dec 2023
Dec 2024
Net Income
-22
-31
-51
-76
-81
-145
-239
1,687
Operating Cash Flow
-18
-23
-32
-47
-80
-115
-193
-194
Investing Cash Flow
-1
-1
-1
-1
0
0
-4
-2
Financing Cash Flow
13
13
43
166
83
258
201
71
Change in Cash
-6
-11
9
117
2
142
4
-125

Global Institutional Holdings in Inhibrx Biosciences, Inc.

Funds
Holdings
DekaBank Deutsche Girozentrale
0%
Advisor Group Holdings, Inc.
0%

Insights on Inhibrx Biosciences, Inc.

Insights help you understand the recent movement of the company's critical parameters, giving you an overall view of the company.

  • imgPOSITIVE IMPACT

    Revenue Rich

    img

    Revenue is up for the last 2 quarters, 100.0K → 1.3M (in $), with an average increase of 92.3% per quarter

  • imgPOSITIVE IMPACT

    Price Rise

    img

    In the last 3 months, INBX stock has moved up by 86.2%

  • imgPOSITIVE IMPACT

    Profit Spike

    img

    Netprofit is up for the last 3 quarters, -47.86M → -28.65M (in $), with an average increase of 30.8% per quarter

  • imgNO EFFECT

    Against Peers

    img

    In the last 1 year, Beone Medicines Ltd has given 68.2% return, outperforming this stock by 10.3%

  • imgNO EFFECT

    Against Peers

    img

    In the last 3 years, Alnylam Pharmaceuticals, Inc. has given 111.5% return, outperforming this stock by 23.5%

About Inhibrx Biosciences, Inc.

Inhibrx Biosciences, Inc. is a clinical-stage biopharmaceutical company focused on developing a broad pipeline of novel biologic therapeutic candidates. The Company utilizes diverse methods of protein engineering to address the specific requirements of complex target and disease biology, including its proprietary protein engineering platforms. Its clinical pipeline of therapeutic candidates includes ozekibart (INBRX-109) and INBRX-106. INBRX-109 is a tetravalent agonist of death receptor 5 (DR5) that it designed with its proprietary single domain antibody (sdAb) platform to drive cancer-selective programmed cell death and to maximize potency while minimizing on-target liver toxicity arising from hepatocyte apoptosis. INBRX-106 is a hexavalent OX40 agonist which is being investigated as a single agent and in combination with KEYTRUDA (pembrolizumab), a PD-1 blocking checkpoint inhibitor, in patients with locally advanced or metastatic solid tumors.
OrganisationInhibrx Biosciences, Inc.
Headquarters11025 North Torrey Pines Road, La Jolla, CA, United States, 92037
IndustryHealth Technology
CEOMr. Mark Paul Lappe
E-voting on sharesClick here to vote

Key Management of Inhibrx Biosciences, Inc.

Name

Title

Mr. David J. Matly M.B.A.

President

Ms. Bonne Adams M.B.A.

Vice President of Operations

Dr. Ashraf Amanullah Ph.D.

Executive VP & Chief Technical Operations Officer

Dr. Carlos Bais Ph.D.

EVP & Chief Scientific Officer

Ms. Leah Pollema J.D.

VP, General Counsel & Corporate Secretary

Dr. Josep Garcia Ph.D.

Executive VP & Chief Clinical Development Officer

Mr. Mark Paul Lappe

Founder, CEO & Chairman

Ms. Kelly Devine Deck B.S., CPA, M.S.

Executive VP, CFO & Treasurer

FAQs

What is Inhibrx Biosciences, Inc. share price today?

Inhibrx Biosciences, Inc. share price today is $26.52 as on at the close of the market. Inhibrx Biosciences, Inc. share today touched a day high of $27.89 and a low of $26.28.

What is the 52 week high and 52 week low for Inhibrx Biosciences, Inc. share?

Inhibrx Biosciences, Inc. share touched a 52 week high of $30.23 on and a 52 week low of $10.81 on . Inhibrx Biosciences, Inc. stock price today i.e. is closed at $26.52,which is 12.27% down from its 52 week high and 145.44% up from its 52 week low.

What is Inhibrx Biosciences, Inc. 's market capitalisation today?

Inhibrx Biosciences, Inc. market capitalisation is $0.00T as on .

How to invest in Inhibrx Biosciences, Inc. Stock (INBX) from India?

  1. Step 1: Open a free US stocks account on INDmoney App and transfer your Rupees into Dollars to your INDmoney US stocks account. For a step by step instruction, check How to Transfer Money to Your US Stocks Account .
  2. Step 2: Search for Inhibrx Biosciences, Inc. on INDmoney app. Click on Buy button. You can invest as low as $1.5 in Inhibrx Biosciences, Inc. Shares that will get you 0.0566 shares as per Inhibrx Biosciences, Inc. share price of $26.52 per share as on September 17, 2025 at 1:29 am IST.

What is the minimum amount required to buy Inhibrx Biosciences, Inc. Stock (INBX) from India?

Indian investors can start investing in Inhibrx Biosciences, Inc. (INBX) shares with as little as ₹88.042 or $1 (as of ) using the INDmoney app.
For example: If you want to invest $10 or ₹880.42 in Inhibrx Biosciences, Inc. stock (as per the Rupee-Dollar exchange rate as on ). Based on Inhibrx Biosciences, Inc. share’s latest price of $26.52 as on September 17, 2025 at 1:29 am IST, you will get 0.3771 shares of Inhibrx Biosciences, Inc. . Learn more about fractional shares .

What are the returns that Inhibrx Biosciences, Inc. has given to Indian investors in the last 5 years?

Inhibrx Biosciences, Inc. stock has given 44.17% share price returns and 20.01% dollar appreciation to an Indian investor in the last 5 years.
Read more about How do Currency Exchange Rates impact your returns on US Stock Investments?